To further explore the biological properties of IGF2BP3 in RCC progression, we designed a CRISPR‐sgRNA or a plasmid vehicle to specifically regulate IGF2BP3 expression in RCC cell lines (Figure S2A). The gene discussed is IGF2BP3; the disease is renal cell carcinoma.